Some of the most common changes in non-small cell lung cancer are changes in the EGFR gene. Gilotrif, Iressa, Tagrisso and Tarceva are oral drugs. They are used to target multiple, different types of EGFR changes.
Portrazza targets EGFR and is given by vein. It is approved for a type of NSCLC called squamous cell. It is given with chemotherapy.